Inogen Stock Gains Following Q2 Earnings Beat, Revenues Up Y/Y

Inogen (INGN) reported a narrower-than-expected adjusted loss of $0.02 per share for Q2 2025, significantly beating consensus estimates, alongside revenues of $92.3 million, which grew 4% year-over-year and surpassed expectations. This top-line growth was primarily fueled by strong domestic and international business-to-business sales, up 19.3% and 17.7% respectively, although partially offset by declines in direct-to-consumer and rental revenues. Despite a 360 basis point contraction in adjusted gross margin, reduced operating expenses contributed to a narrower operating loss, and the company maintained its 2025 revenue guidance of $354-$357 million, while shares gained 2.7% pre-market following the announcement, albeit remaining down 36% year-to-date.

Analysis

Inogen (INGN) reported a mixed but better-than-feared second quarter, with an adjusted loss per share of $0.02 significantly outperforming the consensus estimate of a $0.22 loss. Total revenue grew 4% year-over-year to $92.3 million, also beating forecasts, driven by a pronounced strategic shift towards business-to-business (B2B) channels, where domestic and international sales surged 19.3% and 17.7% respectively. However, this growth was offset by persistent weakness in the higher-margin direct-to-consumer segment, which fell 21.1%, and an 8.6% decline in rental revenues. This unfavorable revenue mix contributed to a significant 360 basis point contraction in adjusted gross margin to 48.1%. While management demonstrated cost control by reducing adjusted operating expenses by 3.9%, the company still posted a $2.6 million adjusted operating loss. The balance sheet remains debt-free, but cash burn is a notable concern, with cash and equivalents declining by $15.2 million during the quarter and operating cash flow swinging to a $12.4 million use of cash from a $1.9 million source in the prior year. The company's reaffirmed full-year revenue guidance of $354-$357 million suggests confidence, but the stock's 36% year-to-date decline underscores investor concern about the path to sustained profitability.

Key Decisions for Investors

• Investors should scrutinize the ongoing revenue mix shift, as strong growth in lower-margin B2B channels is currently insufficient to offset declines in direct-to-consumer sales and drive overall profitability.
• The negative operating cash flow of $12.4 million and the quarterly reduction in cash reserves are critical risk factors; monitor the cash burn rate closely in subsequent quarters against the company's progress toward breakeven.
• Despite the positive earnings surprise, consider the stock's significant underperformance relative to peers and the broader market, and wait for evidence of stabilizing gross margins and a clear path to positive operating income before viewing this as a confirmed turnaround.
• Evaluate management's execution on new initiatives like the Voxi 5 concentrator and Patient Portal for their potential to improve the revenue mix and support long-term growth.